☆ 4.6 Article

Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study

BLOOD ADVANCES (2023)

Related references

Note: Only part of the references are listed.

Review Hematology

Therapeutic options for relapsed/refractory mantle cell lymphoma

Toby A. Eyre et al.

Summary: This review discusses the key therapeutic approaches in the management of relapsed mantle cell lymphoma (MCL), with a focus on the use of covalent Bruton tyrosine kinase (BTK) inhibitors. The review also explores treatment options after BTK inhibitor therapy, including chimeric antigen receptor T-cell therapy and novel therapies.

BLOOD (2022)

Add to Collection

Article Medicine, General & Internal

Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenstrom's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study

Xin-Xin Cao et al.

Summary: Orelabrutinib has shown good efficacy and manageable safety profiles in patients with relapsed or refractory Waldenstrom's macroglobulinemia (R/R WM). The primary endpoint of this prospective study was to evaluate the major response rate (MRR) of orelabrutinib, which was found to be 80.9%, with an overall response rate of 89.4%.

ECLINICALMEDICINE (2022)

Add to Collection

Letter Oncology

Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials

Keshu Zhou et al.

Summary: Zanubrutinib monotherapy demonstrates good efficacy and safety in relapsed/refractory MCL, with high overall response rate and complete response rate. Results suggest better performance in patients treated in the second-line setting.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection

Article Hematology

Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma

Constantine S. Tam et al.

Summary: Zanubrutinib showed good tolerability and activity in patients with relapsed/refractory mantle cell lymphoma, with an overall response rate of 84% and a median progression-free survival of 21.1 months.

BLOOD ADVANCES (2021)

Add to Collection

Review Oncology

Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances

Tingyu Wen et al.

Summary: BTK inhibitor ibrutinib has revolutionized the management of B-cell malignancies by creating a chemotherapy-free era, with sales exceeding 230 billion dollars in just 6 years and becoming one of the top five best-selling medicines globally. Numerous clinical trials of BTK inhibitors were initiated in the past decade, with around 73 trials intensively announced or updated in the most recent 3 years.

LEUKEMIA (2021)

Add to Collection

Article Oncology

Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase

Yuqin Song et al.

CLINICAL CANCER RESEARCH (2020)

Add to Collection

Letter Oncology

Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma

Michael Wang et al.

LEUKEMIA (2019)

Add to Collection

Article Medicine, General & Internal

Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial

Michael Wang et al.

LANCET (2018)

Add to Collection

Review Biochemistry & Molecular Biology

Role of Bruton's tyrosine kinase in B cells and malignancies

Simar Pal Singh et al.

MOLECULAR CANCER (2018)

Add to Collection

Article Pharmacology & Pharmacy

Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile

Tjeerd Barf et al.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2017)

Add to Collection

Article Hematology

Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management

Julie M. Vose

AMERICAN JOURNAL OF HEMATOLOGY (2017)

Add to Collection

Article Oncology

2016 US Lymphoid Malignancy Statistics by World Health Organization Subtypes

Lauren R. Teras et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2016)

Add to Collection

Review Oncology

Mantle Cell Lymphoma

Chan Yoon Cheah et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

Add to Collection

Article Hematology

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

Michael L. Wang et al.

BLOOD (2015)

Add to Collection

Article Oncology

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

Bruce D. Cheson et al.

JOURNAL OF CLINICAL ONCOLOGY (2014)

Add to Collection

Article Medicine, General & Internal

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

Michael L. Wang et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Add to Collection

Article Hematology

The role of FDG-PET scans in patients with lymphoma

Pamela Seam et al.

BLOOD (2007)

Add to Collection

Article Oncology

Response assessment of aggressive non-Hodgkin's lymphoma by integrated international workshop criteria and fluorine-18-fluorodeoxyglucose positron emission tomography

ME Juweid et al.

JOURNAL OF CLINICAL ONCOLOGY (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.